drugset
drugset / Trial / NCT00909688

Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses

NCT00909688 ↗

Phase 1 Completed 16 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupTriple-blindOther

Summary

To determine the safety, tolerability, and drug absorption profile of multiple IV doses of BLI 489 in healthy subjects.

Timeline

Start
2009-06-05
Primary completion
2009-07-24
Completion
2009-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject BLI-489 Small molecule — Intravenous

Indications

No indication recorded.